SCHEMBL24253855

SCHEMBL24253855

Cn1nc(OC2CCOCC2)cc(N2CCC3(CCCC(=O)N3c3ccc(F)c(F)c3)CC2)c1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 3/20 0.34
TRPV4 Q9HBA0 1/20 0.34
CREBBP Q92793 3/20 0.32
BRD4 O60885 2/20 0.32
BRD2 P25440 1/20 0.32
BRD3 Q15059 1/20 0.32
BRDT Q58F21 1/20 0.32
BRD9 Q9H8M2 1/20 0.32
CACNB4 O00305 1/20 0.32
CACNA1A O00555 1/20 0.32
CACNA1G O43497 1/20 0.32
CACNG3 O60359 1/20 0.32
CACNA1F O60840 1/20 0.32
CACNA1H O95180 1/20 0.32
CACNB3 P54284 1/20 0.32
CACNA2D1 P54289 1/20 0.32
CACNG7 P62955 1/20 0.32
CACNA1B Q00975 1/20 0.32
CACNA1D Q01668 1/20 0.32
CACNB1 Q02641 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30423647 1.00 EP300 (0.34) EP300TRPV4CREBBPBRD4BRD2
SCHEMBL24253519 0.86 HCRTR1 (0.33) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL30423965 0.85 EP300 (0.32) EP300CREBBPBRD4BRD2BRD3
SCHEMBL24253508 0.85 EP300 (0.32) EP300CREBBPBRD4BRD2BRD3
SCHEMBL24253950 0.81 GPR119 (0.36) EP300
SCHEMBL30423914 0.80 PDE10A (0.37) EP300TRPV4CREBBPBRD4BRD2
SCHEMBL24253951 0.80 PDE10A (0.37) EP300TRPV4CREBBPBRD4BRD2
SCHEMBL30423903 0.78 PDE10A (0.41) EP300TRPV4
SCHEMBL24253653 0.78 PDE10A (0.41) EP300TRPV4
SCHEMBL24253647 0.78 EP300 (0.35) EP300TRPV4CREBBPBRD4BRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 EP300 1224/4885TRPV4 350/4885CREBBP 2408/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 EP300 1224/4885TRPV4 350/4885CREBBP 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.